PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
1213.79%
Net income growth above 1.5x CSIQ's 158.41%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
3.56%
D&A growth of 3.56% while CSIQ is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
-398.64%
Negative yoy deferred tax while CSIQ stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
-15.50%
Negative yoy SBC while CSIQ is 0.00%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-106.96%
Negative yoy working capital usage while CSIQ is 36.36%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
522.30%
AR growth of 522.30% while CSIQ is zero at 0.00%. Bruce Berkowitz would see a mild difference in credit approach that could matter for cash flow.
-255.62%
Negative yoy inventory while CSIQ is 0.00%. Joel Greenblatt would see a near-term cash advantage if top-line doesn't suffer.
-63.13%
Negative yoy AP while CSIQ is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
84.10%
Growth well above CSIQ's 36.36%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
295.06%
Well above CSIQ's 126.30%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-79.62%
Negative yoy CFO while CSIQ is 171.37%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-146.40%
Both yoy lines negative, with CSIQ at -1.91%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
-328653.01%
Negative yoy acquisition while CSIQ stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
32.67%
Purchases growth of 32.67% while CSIQ is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
-83.63%
We reduce yoy sales while CSIQ is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
-266.29%
We reduce yoy other investing while CSIQ is 33.39%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-108803.59%
We reduce yoy invests while CSIQ stands at 4.41%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
-100.00%
We cut debt repayment yoy while CSIQ is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
-90.63%
Both yoy lines negative, with CSIQ at -13.16%. Martin Whitman would see an overall reduced environment for buybacks in the niche or cyclical factor driving capital usage.